Please ensure Javascript is enabled for purposes of website accessibility

Timing is Everything for this Health Care IT Provider

By Seth Robey - Feb 3, 2014 at 6:30PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Veeva Systems has an innovative platform to meet the growing demand for cost-cutting in the health care sector.

Veeva Systems (VEEV -2.31%) has been turning heads recently, as it unrolls its data cloud for the life sciences industry. In a space dominated by big players like (CRM -2.21%) and Oracle, Veeva has been carving out a niche for itself servicing some of health care's biggest players. Its platform of logistical cloud-based software for customer relationship management (CRM) is designed specifically to help drug makers operate more efficiently. Finding its place at the union of health care and tech, Veeva seems to have hit the scene at just the right time.

Early, but not too early
Veeva has come on the scene during a huge tech and biotech IPO season. With the market at all time highs and investors looking for exciting new opportunities, conditions are ripe for young development stage companies to go public and raise funds. Those conditions allowed Veeva to effectively raise north of $260 million while still maintaining a spotless balance sheet.

While Veeva is certainly young, it's one of an elite class of tech IPOs that hit the market with a profitable business. With big name customers like Eli Lilly (LLY 1.91%), Merck, and Novartis, it's clear that market penetration is not an early headwind. In its first quarterly report, Veeva listed $6.5 million in net income on $55 million of revenue in its first quarter as a publicly traded company.

Late, but not too late
With, Oracle, and even Web Services paving the way for cloud computing, Veeva is by no means a technological pioneer and in that sense is late to the cloud computing party. But it's not too late. The industry as a whole still has plenty of room to evolve, and Veeva's platform stands out as an innovative application of SaaS and CRM. In fact, Veeva's relationship with is a key component of its business model. CEO Peter Gassner was former Senior VP of Technology at and has built Veeva's software on the structure of's platform. stands to benefit from the relationship, too. A value-added reseller agreement grants Veeva exclusive industry rights to the Salesforce Platform and kicks an undisclosed fee. The partnership highlights the versatility of's platform and helps the company diversify into an untapped market. It also represents a source of high margin growth for, as it distributes the fixed costs of its cloud infrastructure over new revenue streams.

Just Right
One of the major running story lines has been the impending doom of the patent cliff. That threat of diminishing revenue from generic competition has forced major cost-cutting to curb R&D and SG&A spending and streamline operations for many pharmaceutical companies.

Eli Lilly, one of Veeva's subscribers, is a good example of a big pharma player with struggling revenue streams and bloated costs. Lilly is facing generic competition for blockbusters Zyprexa and Cymbalta, and has invested billions to replace those drugs with new therapies. They haven't seen a great return on that investment, though, after Alzheimer's drug solanezumab and cancer therapy ramicurimab failed to live up to expectations. That's caused expenses to continue to balloon, and Lilly has resisted the wave of major restructuring that has overtaken its big pharma peers. Veeva is primed perfectly to lend a hand to a company like Eli Llly.

LLY Revenue (TTM) Chart

LLY Revenue (TTM) data by YCharts

Veeva CRM, the company's cornerstone product, connects sales reps with management through any Internet connection. That allows management to collect information and sales data from any customer, selectively distribute targeted marketing campaigns directly to representatives, and identify marketing inefficiencies to reduce cost.

On the development front, Veeva has unrolled Veeva Vault, designed to seamlessly coordinate clinical trial execution. An overwhelming amount of paperwork goes into trial design, data collection, analysis, and regulatory filing. Vault provides a single cloud-based interface to facilitate all of those processes and trim out inefficiencies. Vault represents Veeva's real growth prospect, and the challenge will be to create a full ecosystem of cloud-based operations by converting CRM users into Vault users.

The bottom line
Just because Veeva has come along at a wonderful time when health care demands IT solutions for its efficiency problems doesn't mean that now is the right time to jump in as an investor. The case presented here lays out some very bullish arguments for Veeva's growth, but when a company's stock is trading at nearly 200 times trailing earnings you better be sure to understand the potential pitfalls, as well. Check back soon, when I'll breakdown some of the headwinds Veeva will face moving forward.

Seth Robey owns shares of The Motley Fool recommends and The Motley Fool owns shares of and Oracle.. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Veeva Systems Inc. Stock Quote
Veeva Systems Inc.
$219.21 (-2.31%) $-5.19
Salesforce, Inc. Stock Quote
Salesforce, Inc.
$183.77 (-2.21%) $-4.16
Eli Lilly and Company Stock Quote
Eli Lilly and Company
$322.77 (1.91%) $6.05

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/19/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.